A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Latest Information Update: 14 Nov 2024
At a glance
- Drugs Bemnifosbuvir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms SUNRISE-3
- Sponsors Atea Pharmaceuticals
- 07 Nov 2024 According to an Atea pharmaceuticals media release, Given the trial results and the changing landscape of the pandemic, Atea will not pursue a regulatory pathway forward for bemnifosbuvir for COVID-19.
- 13 Sep 2024 Primary endpoint (Proportion of subjects hospitalized for any cause or died due to any cause) has not been met as per results presented in the Atea pharmaceuticals Media Release.
- 13 Sep 2024 Results presented in the Atea pharmaceuticals Media Release.